AstraZeneca to present four key trials at ESMO

AstraZeneca (AZN) announces new data across its portfolio and pipeline at the European Society for Medical Oncology, ESMO, Congress, October 17-21, 2025. More than 95 abstracts will feature nine approved and nine potential new medicines from the Company including two abstracts featured in a late-breaking Presidential Symposium and 26 oral presentations. Key presentations include: DESTINY-Breast11 Phase III trial of Enhertu followed by paclitaxel, trastuzumab and pertuzumab when used in the neoadjuvant setting in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. DESTINY-Breast05 Phase III trial of Enhertu as post-neoadjuvant therapy in patients with HER2-positive early breast cancer with high risk of disease recurrence. TROPION-Breast02 Phase III trial of Datroway as 1st-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option. POTOMAC Phase III trial of Imfinzi plus standard-of-care BCG induction and maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer. MATTERHORN: Final overall survival results from the Phase III trial of perioperative Imfinzi plus FLOT chemotherapy in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.